118 related articles for article (PubMed ID: 17526058)
1. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5.
Kesavapany S; Zheng YL; Amin N; Pant HC
Biotechnol J; 2007 Aug; 2(8):978-87. PubMed ID: 17526058
[TBL] [Abstract][Full Text] [Related]
2. A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes.
Pao PC; Seo J; Lee A; Kritskiy O; Patnaik D; Penney J; Raju RM; Geigenmuller U; Silva MC; Lucente DE; Gusella JF; Dickerson BC; Loon A; Yu MX; Bula M; Yu M; Haggarty SJ; Tsai LH
Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2217864120. PubMed ID: 37043533
[TBL] [Abstract][Full Text] [Related]
3. Changes in the prefrontal cortex after the hippocampus was injected with Aβ
Wang Y; Sheng H; Zhao J; Guo L; Liu J; Xu J; Liu Q; Huang J; Jiang R; Gan S; Qiu G; Lu W; Xu S; Zhu S
Neurosci Lett; 2021 Jan; 741():135453. PubMed ID: 33186609
[TBL] [Abstract][Full Text] [Related]
4. Unveiling Potential Neurotoxic Mechansisms: Pb-Induced Activation of CDK5-p25 Signaling Axis in Alzheimer's Disease Development, Emphasizing CDK5 Inhibition and Formation of Toxic p25 Species.
Lokesh M; Bandaru LJM; Rajanna A; Rao JS; Challa S
Mol Neurobiol; 2024 May; 61(5):3090-3103. PubMed ID: 37968421
[TBL] [Abstract][Full Text] [Related]
5. Generation of the Cdk5 activator p25 is a memory mechanism that is affected in early Alzheimer's disease.
Giese KP
Front Mol Neurosci; 2014; 7():36. PubMed ID: 24822036
[TBL] [Abstract][Full Text] [Related]
6. The neuronal p35 activator of Cdk5 is a novel F-actin binding and bundling protein.
He L; Zhang Z; Yu Y; Ahmed S; Cheung NS; Qi RZ
Cell Mol Life Sci; 2011 May; 68(9):1633-43. PubMed ID: 20976519
[TBL] [Abstract][Full Text] [Related]
7. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.
Chatterjee A; Cutler SJ; Doerksen RJ; Khan IA; Williamson JS
Bioorg Med Chem; 2014 Nov; 22(22):6409-21. PubMed ID: 25438765
[TBL] [Abstract][Full Text] [Related]
8. Protocols for Characterization of Cdk5 Kinase Activity.
Terse A; Amin N; Hall B; Bhaskar M; B K B; Utreras E; Pareek TK; Pant H; Kulkarni AB
Curr Protoc; 2021 Oct; 1(10):e276. PubMed ID: 34679246
[TBL] [Abstract][Full Text] [Related]
9. Three decades of Cdk5.
Pao PC; Tsai LH
J Biomed Sci; 2021 Nov; 28(1):79. PubMed ID: 34814918
[TBL] [Abstract][Full Text] [Related]
10. Computational Simulations Identify Pyrrolidine-2,3-Dione Derivatives as Novel Inhibitors of Cdk5/p25 Complex to Attenuate Alzheimer's Pathology.
Zeb A; Kim D; Alam SI; Son M; Kumar R; Rampogu S; Parameswaran S; Shelake RM; Rana RM; Parate S; Kim JY; Lee KW
J Clin Med; 2019 May; 8(5):. PubMed ID: 31137734
[No Abstract] [Full Text] [Related]
11. CDK5: an oncogene or an anti-oncogene: location location location.
Nikhil K; Shah K
Mol Cancer; 2023 Nov; 22(1):186. PubMed ID: 37993880
[TBL] [Abstract][Full Text] [Related]
12. Identification of Novel Compounds Inhibiting the Kinase Activity of the CDK5/p25 Complex via Direct Binding to p25.
Jabeur R; Corbel C; Loyer P; Le Parc A; Le Grand A; Comte A; Bach S; André-Leroux G; Sire O; Ben Mansour H; Le Tilly V
Biochemistry; 2023 May; 62(9):1452-1463. PubMed ID: 37074084
[TBL] [Abstract][Full Text] [Related]
13. Role of CDK5/cyclin complexes in ischemia-induced death and survival of renal tubular cells.
Guevara T; Sancho M; Pérez-Payá E; Orzáez M
Cell Cycle; 2014; 13(10):1617-26. PubMed ID: 24675881
[TBL] [Abstract][Full Text] [Related]
14. Drosophila lacking the Cdk5 activator, p35, display defective axon guidance, age-dependent behavioral deficits and reduced lifespan.
Connell-Crowley L; Vo D; Luke L; Giniger E
Mech Dev; 2007 May; 124(5):341-9. PubMed ID: 17368005
[TBL] [Abstract][Full Text] [Related]
15. Nestin as a regulator of Cdk5 in differentiating myoblasts.
Pallari HM; Lindqvist J; Torvaldson E; Ferraris SE; He T; Sahlgren C; Eriksson JE
Mol Biol Cell; 2011 May; 22(9):1539-49. PubMed ID: 21346193
[TBL] [Abstract][Full Text] [Related]
16. TFP5, a Peptide Derived from Cdk5 Activator p35, Protects Pancreatic β Cells from Glucose Toxicity.
Liu SY; Cao SL; Luo HY; Bao L; E J; Li B; Lan XM; Zhang GQ; Bao X; Zheng YL
Bull Exp Biol Med; 2023 Nov; 176(1):19-25. PubMed ID: 38087140
[TBL] [Abstract][Full Text] [Related]
17. Cdk5 activation promotes Cos-7 cells transition towards neuronal-like cells.
Bao L; Lan XM; Zhang GQ; Bao X; Li B; Ma DN; Luo HY; Cao SL; Liu SY; Jing E; Zhang JZ; Zheng YL
Transl Neurosci; 2023 Jan; 14(1):20220318. PubMed ID: 37901140
[TBL] [Abstract][Full Text] [Related]
18. CDK5 as a therapeutic tool for the treatment of Alzheimer's disease: A review.
Garemilla S; Kumari R; Kumar R
Eur J Pharmacol; 2024 Jun; 978():176760. PubMed ID: 38901526
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo.
Sundaram JR; Poore CP; Sulaimee NH; Pareek T; Asad AB; Rajkumar R; Cheong WF; Wenk MR; Dawe GS; Chuang KH; Pant HC; Kesavapany S
J Neurosci; 2013 Jan; 33(1):334-43. PubMed ID: 23283346
[TBL] [Abstract][Full Text] [Related]
20. Profiling of p5, a 24 Amino Acid Inhibitory Peptide Derived from the CDK5 Activator, p35 CDKR1 Against 70 Protein Kinases.
Binukumar BK; Pelech SL; Sutter C; Shukla V; Amin ND; Grant P; Bhaskar M; Skuntz S; Steiner J; Pant HC
J Alzheimers Dis; 2016 Sep; 54(2):525-33. PubMed ID: 27567857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
